Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS

BACKGROUND: The homogentisic acid‐lowering therapy nitisinone is being evaluated for the treatment of alkaptonuria (AKU) at the National Centre for AKU. Beyond hypertyrosinemia, the wider metabolic consequences of its use are largely unknown. The aim of this work was to evaluate the impact of nitisi...

Descripción completa

Detalles Bibliográficos
Autores principales: Davison, Andrew S., Norman, Brendan P., Ross, Gordon A., Hughes, Andrew T., Khedr, Milad, Milan, Anna M., Gallagher, James A., Ranganath, Lakshminarayan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606987/
https://www.ncbi.nlm.nih.gov/pubmed/31392115
http://dx.doi.org/10.1002/jmd2.12042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6606987/
https://www.ncbi.nlm.nih.gov/pubmed/31392115
http://dx.doi.org/10.1002/jmd2.12042

Ejemplares similares